Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia

Abstract Iloperidone is a mixed D2/5-HT2 antagonist in development for treatment of schizophrenia. This trial aimed to evaluate the efficacy and safety of a fixed dose of iloperidone in patients with acute exacerbations of schizophrenia. This randomized, placebo-controlled, multicenter study comprised a 1-week titration period and a 3-week double-blind maintenance period. Eligible patients (n = 593) were randomized to iloperidone 24 mg/d, ziprasidone 160 mg/d as an active control, or placebo. Primary efficacy variable was change from baseline in the Positive and Negative Syndrome Scale Total (PANSS-T) score, using a mixed-effects model repeated measures analysis. Iloperidone demonstrated significant reduction versus placebo on the PANSS-T score (P< 0.01). Significant improvement versus placebo was also demonstrated with ziprasidone (P < 0.05). Compared with ziprasidone, iloperidone was associated with lower rates of many adverse events (AEs) that are particularly troublesome with antipsychotics, including sedation, somnolence, extrapyramidal symptoms, akathisia, agitation, and restlessness; iloperidone was associated with higher rates of weight gain, tachycardia, orthostatic hypotension, dizziness, and nasal congestion as reported as an AE. Most AEs were mild to moderate. A similar amount of QT prolongation was observed with both active treatments, although no patient had a treatment-emergent postbaseline corrected QT interval of 500 msec or greater. The incidence of clinically relevant changes in laboratory parameters was comparable between iloperidone and ziprasidone. Iloperidone was associated with a low incidence of extrapyramidal symptoms. Overall, there was improvement in akathisia with iloperidone treatment. Iloperidone treatment was effective, safe, and well tolerated in patients with acute exacerbation of schizophrenia.

[1]  M. Polymeropoulos,et al.  Safety Profile of Iloperidone: A Pooled Analysis of 6-Week Acute-Phase Pivotal Trials , 2008, Journal of clinical psychopharmacology.

[2]  M. Polymeropoulos,et al.  Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. , 2008, Pharmacogenomics.

[3]  J. Newcomer,et al.  Series introduction and cardiovascular disease in patients with schizophrenia. , 2007, The Journal of clinical psychiatry.

[4]  P. Weiden.  Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. , 2007, The Journal of clinical psychiatry.

[5]  David Taylor,et al.  A review of atypical antipsychotic drugs versus conventional medication in schizophrenia , 2006, Expert opinion on pharmacotherapy.

[6]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[7]  J. McGough,et al.  Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. , 2005, The American journal of psychiatry.

[8]  G. Chouinard,et al.  Manual for the Extrapyramidal Symptom Rating Scale (ESRS) , 2005, Schizophrenia Research.

[9]  Geert Molenberghs,et al.  The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA , 2004, Clinical trials.

[10]  D. Daniel.  Tolerability of ziprasidone: an expanding perspective. , 2003, The Journal of clinical psychiatry.

[11]  P. Schoeffter,et al.  Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. , 2003, Life sciences.

[12]  Geert Molenberghs,et al.  Assessing and interpreting treatment effects in longitudinal clinical trials with missing data , 2003, Biological Psychiatry.

[13]  D. Hoyer,et al.  Extended Radioligand Binding Profile of Iloperidone: A Broad Spectrum Dopamine/Serotonin/Norepinephrine Receptor Antagonist for the Management of Psychotic Disorders , 2001, Neuropsychopharmacology.

[14]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[15]  K. Jain.  An assessment of iloperidone for the treatment of schizophrenia , 2000, Expert opinion on investigational drugs.

[16]  E. Richelson,et al.  Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. , 2000, Life sciences.

[17]  Jean Addington,et al.  A depression rating scale for schizophrenics , 1990, Schizophrenia Research.

[18]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[19]  Tomas Palenicek,et al.  Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia , 2006, CNS drugs.

[20]  M. Lambert,et al.  Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life , 2004, CNS drugs.

[21]  P. Schoeffter,et al.  Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. , 2003, Life sciences.

[22]  M. Twohig,et al.  Evaluating the efficacy of habit reversal: comparison with a placebo control. , 2003, The Journal of clinical psychiatry.

[23]  John G Csernansky,et al.  Relapse and Rehospitalisation Rates in Patients with Schizophrenia , 2002, CNS drugs.

[24]  H. Meltzer,et al.  Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[25]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.